Abstract
Background: Tuberculosis (TB) is one of the most important causes of mortality due to infectious diseases. The development of a vaccine inducing superior protection than BCG is a top priority for the future control of the disease.
Methods: We reviewed the literature related with the impact of the host, microbiome and environmental elements in response to vaccination, with special emphasis on TB.
Results: This review introduces the term “Self-Antigenic Universe” (SAU) which consists of “Host” & “Guests” (classical microbiota and other organisms with relatively stable presence in the host) and “Familiar Visitors”: (organisms and substances which are often present in the host). We provide multiple examples of how SAU influences the immune response to Mycobacterium tuberculosis and its impact on TB vaccine development.
Conclusion: The immune response induced by antigens/epitopes present in SAU could have carrier effect and elicit specific effector and/or regulatory immune responses potentially useful for the development of new vaccines. This aspect should be considered for the development of tailored vaccines with superior efficacy for the prevention of TB.
Keywords: Mycobacterium tuberculosis, microbiota, vaccine, host, tuberculosis, self, immune response.
Current Pharmacogenomics and Personalized Medicine
Title:“Self-Antigenic Universe” and Tuberculosis Vaccine Development
Volume: 13 Issue: 1
Author(s): Maria E. Sarmiento, Armando Acosta and Mohd Nor Norazmi
Affiliation:
Keywords: Mycobacterium tuberculosis, microbiota, vaccine, host, tuberculosis, self, immune response.
Abstract: Background: Tuberculosis (TB) is one of the most important causes of mortality due to infectious diseases. The development of a vaccine inducing superior protection than BCG is a top priority for the future control of the disease.
Methods: We reviewed the literature related with the impact of the host, microbiome and environmental elements in response to vaccination, with special emphasis on TB.
Results: This review introduces the term “Self-Antigenic Universe” (SAU) which consists of “Host” & “Guests” (classical microbiota and other organisms with relatively stable presence in the host) and “Familiar Visitors”: (organisms and substances which are often present in the host). We provide multiple examples of how SAU influences the immune response to Mycobacterium tuberculosis and its impact on TB vaccine development.
Conclusion: The immune response induced by antigens/epitopes present in SAU could have carrier effect and elicit specific effector and/or regulatory immune responses potentially useful for the development of new vaccines. This aspect should be considered for the development of tailored vaccines with superior efficacy for the prevention of TB.
Export Options
About this article
Cite this article as:
Sarmiento E. Maria, Acosta Armando and Norazmi Nor Mohd, “Self-Antigenic Universe” and Tuberculosis Vaccine Development, Current Pharmacogenomics and Personalized Medicine 2015; 13 (1) . https://dx.doi.org/10.2174/187569211301151228153558
DOI https://dx.doi.org/10.2174/187569211301151228153558 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pyruvate Kinase M2: Regulatory Circuits and Potential for Therapeutic Intervention
Current Pharmaceutical Design Magnetic Iron Oxide Nanoparticles for Tumor-Targeted Therapy
Current Cancer Drug Targets Highlights in Peptide Nanoparticle Carriers Intended to Oral Diseases
Current Topics in Medicinal Chemistry A Family of Pleiotropically Acting MicroRNAs in Cancer Progression, miR-200: Potential Cancer Therapeutic Targets
Current Pharmaceutical Design Preclinical Development of New Therapy for Glycogen Storage Diseases
Current Gene Therapy Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical Candidates
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in pH-Sensitive Polymeric Nanoparticles for Smart Drug Delivery in Cancer Therapy
Current Drug Targets Novel Target Sites for Drug Screening: A Special Reference to Cancer, Rheumatoid Arthritis and Parkinson’s Disease
Current Signal Transduction Therapy Advancement and Strategies for the Development of Peptide-drug Conjugates: Pharmacokinetic Modulation, Role and Clinical Evidence against Cancer Management
Current Cancer Drug Targets Editorial: Look for Changes in 2016
Current Molecular Medicine NK Cell, Monocyte and Non T Cell Biomarkers as Prognostic Indicators in Cancer Immunotherapy
Current Cancer Therapy Reviews β-Crosslaps as a Marker for Bone Metastases in Renal Cell Cancer
Recent Patents on Biomarkers Role of Nuclear Imaging in Cardiac Amyloidosis Management: Clinical Evidence and Review of Literature
Current Medical Imaging Activities of Venom Proteins and Peptides with Possible Therapeutic Applications from Bees and WASPS
Protein & Peptide Letters The Chemopreventive and Chemotherapeutic Potentials of Tea Polyphenols
Current Pharmaceutical Biotechnology Key Questions in Metastasis: New Insights in Molecular Pathways and Therapeutic Implications
Current Pharmaceutical Biotechnology New Treatments for Cutaneous Metastatic Melanoma: MAPK Pathway-Targeted and Immune Based Therapies
Anti-Cancer Agents in Medicinal Chemistry Current Guidelines and Strategies in Management of Renal Vein Thrombosis
Current Pediatric Reviews Recent Advances in the Synthesis and Development of Curcumin, its Combinations and Formulations and Curcumin-like Compounds as Anti-infective Agents
Current Medicinal Chemistry Ghrelin and Growth Hormone Secretagogues, Physiological and Pharmacological Aspect
Current Drug Discovery Technologies